Active Biotech AB (publ) (LON:0GQU)

Active Biotech AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	-	-	6.73
Revenue Growth (YoY)	-	-	-	-	-20.18%
Gross Profit	-	-	-	-	6.73
Selling, General & Admin	13.17	13.94	15.06	15.25	13.48
Research & Development	26.67	32.54	42.82	34.54	25.55
Operating Expenses	39.84	46.48	57.89	49.78	39.03
Operating Income	-39.84	-46.48	-57.89	-49.78	-32.31
Interest Expense	-0.18	-0.24	-0.21	-0.03	-0.09
Interest & Investment Income	0.65	0.29	0.05	-	-
Currency Exchange Gain (Loss)	-0.03	0.07	-0.01	0.02	-0.07
EBT Excluding Unusual Items	-39.4	-46.37	-58.05	-49.79	-32.46
Gain (Loss) on Sale of Investments	-	0.57	-0.32	-0.03	0.22
Pretax Income	-39.4	-45.8	-58.37	-49.83	-32.25
Net Income	-39.4	-45.8	-58.37	-49.83	-32.25
Net Income to Common	-39.4	-45.8	-58.37	-49.83	-32.25
Shares Outstanding (Basic)	420	272	234	214	169
Shares Outstanding (Diluted)	420	272	234	214	169
Shares Change (YoY)	54.84%	16.21%	9.23%	26.87%	16.09%
EPS (Basic)	-0.09	-0.17	-0.25	-0.23	-0.19
EPS (Diluted)	-0.09	-0.17	-0.25	-0.23	-0.19
Free Cash Flow	-40.42	-45.74	-54.85	-46.17	-32.22
Free Cash Flow Per Share	-0.10	-0.17	-0.23	-0.22	-0.19
Gross Margin	-	-	-	-	100.00%
Operating Margin	-	-	-	-	-480.39%
Profit Margin	-	-	-	-	-479.48%
Free Cash Flow Margin	-	-	-	-	-479.05%
EBITDA	-38.24	-44.78	-57.89	-48.48	-31.01
D&A For EBITDA	1.6	1.7	0	1.3	1.3
EBIT	-39.84	-46.48	-57.89	-49.78	-32.31

Updated Feb 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.